Can sirolimus-coated balloons overcome current treatment challenges for chronic limb-threatening ischaemia patients?


Eric Secemsky (Boston, USA) and Edward Choke (Singapore) discuss the role of sirolimus-coated balloons in the treatment of peripheral arterial disease (PAD), particularly below the knee, at the Charing Cross (CX) Symposium (25–27 April, London, UK).

With high amputation and reintervention rates amongst the current challenges that interventionists face when treating PAD, experts are still facing a glaring deficit in their tool box while pursuing “long standing and durable treatments for patients that focus on really important outcomes” such as amputation reduction. In light of the cardiology landscape where there is a growing comfort with limus-based stents being considered an effective therapy in the coronary bed, Secemsky and Choke make the case to explore the use of sirolimus-coated balloons in chronic limb-threatening ischaemia (CLTI) patients. These may offer potential safety advantages over their paclitaxel-coated counterparts, say the duo who discuss the early data that has been gathered with the MagicTouch PTA balloon (Concept Medical Inc.) showing remarkable 74% six-month primary patency in below-the-knee arteries and clinical evidence in the pipeline.

This video has been sponsored by Concept Medical Inc.


Please enter your comment!
Please enter your name here